Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tislelizumab combined with R-CHOP for first-line treatment of EBV-positive diffuse large B-cell lymphoma
ChiCTR2100054451Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Epstein-Barr virus-positive diffuse large B-cell lymphoma, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Dec 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2100054451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054451.